<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115999">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906268</url>
  </required_header>
  <id_info>
    <org_study_id>15224913.3.0000.5327</org_study_id>
    <nct_id>NCT01906268</nct_id>
  </id_info>
  <brief_title>Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants</brief_title>
  <official_title>Attentional Bias Modification Treatment (ABMT) as Adjuvant Therapy for Anxiety Disorder Patients Resistent to Antidepressants: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to test the combination of active or placebo Attentional
      Bias Modification Treatment (ABMT) to usual treatment for anxiety disorder patients
      resistant to antidepressants.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Anxiety Severity and Impairment Scale (OASIS)</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disorder non-specific primary outcome:
Score change on OASIS (Overall Anxiety Severity and Impairment Scale) from baseline to endpoint and 3-months follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Panic Disorder Severity Scale (PDSS), Generalized Anxiety Disorder 7-item Scale (GAD-7) or Liebowitz Social Anxiety Scale (LSAS)</measure>
    <time_frame>Endpoint and 3-months follow up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disorder-specific primary outcome:
For patients with Panic Disorder - change from baseline to endpoint and 3 months follow-up in the PDSS
For patients with Generalized Anxiety Disorder - change from baseline to endpoint and 3 months follow-up in the GAD-7
For patients with Social Anxiety Disorder - change from baseline to endpoint and 3 months follow-up in the LSAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score change on BDI from baseline to endpoint and 3-months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score change on BAI from baseline to endpoint and 3-months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM-5 Cross-Disorder Dimensional Scale [Brazilian version]</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score change on Cross-D from baseline to endpoint and 3-months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood States (POMS)</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score Change on POMS from baseline to endpoint and 3-months follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression(CGI)</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dichotomous outcome: percentage of patients with a score of 2 or less at the endpoint and 3-months follow-up evaluations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dot-probe and Executive Function Measures</measure>
    <time_frame>Endpoint and 3-months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in bias in attention orienting and executive function measures from baseline to endpoint and 3-months follow-up</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <condition>Social Anxiety Disorder</condition>
  <condition>Panic Disorder</condition>
  <arm_group>
    <arm_group_label>TAU + ABMT active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor
Attention Bias Modification Treatment (ABMT) - active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU + AMBT placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor
Attention Bias Modification Treatment (ABMT) - placebo (sham)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Attentional Bias Modification Treatment (ABMT) - Active</intervention_name>
    <description>The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (&lt; or &gt;) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)</description>
    <arm_group_label>TAU + ABMT active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Attentional Bias Modification Treatment - Placebo</intervention_name>
    <description>The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)</description>
    <arm_group_label>TAU + AMBT placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of Generalized Anxiety Disorder, Panic Disorder or Social Anxiety
             Disorder according to the International Neuropsychiatric Interview psychiatric
             interview (M.I.N.I.)

          -  Current treatment for the anxiety disorder with antidepressants with an  appropriate
             dose for at least 3 months;

          -  Score on OASIS (Overall Anxiety Severity and Impairment Scale)equal or greater than 8

        Exclusion Criteria:

          -  Other psychiatric disorder that causes more impairment and suffering than generalized
             anxiety disorder, panic disorder or social anxiety disorder in the clinical
             evaluation

          -  Current Cognitive Behavior Therapy

          -  Marked intellectual disability (clinically evident)

          -  Suicidal ideation or suicide plan at the time of assessment(M.I.N.I.)

          -  Psychotic disorder (M.I.N.I.)

          -  Bipolar disorder type I (M.I.N.I.)

          -  Abuse / Dependence substances (M.I.N.I.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisele G Manfro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Montagner, MD</last_name>
    <phone>+55 51 3359 8983</phone>
    <email>rachelmontagner@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90040-371</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90040-371</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rachel Montagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni A Salum Junior</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliana L Muller</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clarissa Trentini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 23, 2013</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized Anxiety Disorder</keyword>
  <keyword>Social Anxiety Disorder</keyword>
  <keyword>Panic Disorder</keyword>
  <keyword>Antidepressants Resistant</keyword>
  <keyword>Attentional Bias Modification Treatment (ABMT)</keyword>
  <keyword>Attentional Retraining</keyword>
  <keyword>Adjuvant Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
